DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $69.77, for a total transaction of $418,620.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin R. Sayer also recently made the following trade(s):

  • On Wednesday, July 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00.
  • On Monday, June 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $69.07, for a total transaction of $414,420.00.

DexCom, Inc. (NASDAQ:DXCM) traded down 0.56% on Tuesday, hitting $71.22. 539,305 shares of the company were exchanged. The company’s market capitalization is $6.16 billion. DexCom, Inc. has a 52 week low of $57.68 and a 52 week high of $96.38. The firm’s 50 day moving average is $70.96 and its 200 day moving average is $75.04.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.24) EPS. On average, equities research analysts forecast that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: DexCom, Inc. (DXCM) CEO Sells 6,000 Shares of Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/15/insider-selling-dexcom-inc-dxcm-ceo-sells-6000-shares-of-stock.html.

A number of research firms have commented on DXCM. TheStreet raised shares of DexCom from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd. BidaskClub raised shares of DexCom from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 9th. B. Riley reissued a “buy” rating and set a $95.00 price objective on shares of DexCom in a research report on Sunday, May 7th. BMO Capital Markets reissued an “outperform” rating and set a $90.00 price objective (down previously from $105.00) on shares of DexCom in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $87.00.

A number of large investors have recently modified their holdings of DXCM. Advisor Group Inc. raised its stake in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of DexCom during the first quarter worth $136,000. IFP Advisors Inc raised its stake in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after buying an additional 159 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom during the first quarter worth $164,000. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares in the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.